Introduction: Phosphatase and tensin homolog (PTEN) loss is frequently observed in NSCLC and associated with both phosphoinositide 3-kinase activation and tumoral immunosuppression. PTEN immunohistochemistry is a valuable readout, but lacks standardized staining protocol and cutoff value.
Introduction
Phosphatase and tensin homolog (PTEN) is a major tumor suppressor with pleiotropic functions on cell survival, proliferation, and chromosomal integrity. 1, 2 Cytosolic loss of function (PTEN-) leads to hyperactivation of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin signaling pathway, an event which is common to NSCLC. 3, 4 Loss of nuclear PTEN leads to an unstable genome with increased mutational burden, sensitizing cells to DNA-targeting drugs such as cisplatin. 5, 6 There is no validated clinically effective special treatment for PTENcancers yet, but substantial research and drug development for the PTEN/PI3K axis is ongoing, in particular regarding PI3K inhibitors, for which PTEN-is a surrogate marker. There are phase I and II clinical trials with PI3K inhibitors in solid tumors and NSCLC, respectively, as well as in castration-resistant prostate carcinoma requiring assessment of PTEN status. [7] [8] [9] PTEN is not only an important predictive biomarker for PI3K inhibition, but it has recently been reported that PTEN-might be a mechanism of resistance to cancer immunotherapy, for example, in metastatic uterine leiomyosarcoma. 10 In mouse melanoma cells, PTENpromoted resistance to T cell-mediated immunotherapy such as anti-programmed death 1/programmed death ligand 1 (PD-L1), by decreasing T cell infiltration and expansion in tumors. 11 Such loss causes an immunesuppressive microenvironment by activation of regulatory T cells and inhibition of natural killer cells. 12, 13 In lung squamous cell carcinomas (LSCC) loss of liver kinase B1 (LKB1) and PTEN led to elevated PD-L1 expression. 14 However, in high-grade lung neuroendocrine carcinoma, no significant correlation among PTEN loss, immune cell infiltration, and PD-L1 expression on either tumor cells or immune cells was found. 15 Finally, there are different micro-RNAs (miR-21, miR-92b, R-26b, and miR-181a) regulating PTEN expression, thereby affecting cell growth, migration, and resistance/sensitivity to platinum-based chemotherapies. 16 The poor prognostic value of PTEN-has been described in various cancers. [17] [18] [19] In NSCLC, two studies in 2012 showed that protein loss as measured by immunohistochemistry (IHC) occurs in up to 21% or up to 59% of LSCC. For lung adenocarcinomas (LADC), the frequencies were 4% and 34%, respectively. 20, 21 Both studies used the 138G6 antibody and PTEN-was defined as absence of any immunoreactivity. An earlier study in 2005 found a complete loss or reduced PTEN protein expression in 74% of NSCLC, whereby reduced expression was defined as positive staining of any intensity in less than 50% of the tumor cells using the 6H2.1 antibody. 22 In high-grade lung neuroendocrine carcinoma, complete loss of PTEN protein was found in 9.5% using the 28H6 antibody. 15 Therefore, clinical assessment of PTEN status is important, but lacks standards. Determination of protein loss by IHC is considered the best approach, as it integrates various regulatory networks acting on the enzyme. IHC is assumed to be superior to sequencing because more PTEN-cases have been detected by IHC than by sequencing in endometrial carcinoma. 23 In particular, PTEN protein loss was detected by IHC in 44% of cases classified as PTEN wild-type by sequencing. In high-grade lung neuroendocrine carcinomas, PTEN IHC expression had no correlation with PTEN mutation status assessed by genomic analysis. 15 Given that PTEN is a tumor suppressor, protein loss rather than overexpression is pathologically and clinically relevant. Therefore, the low-level expression range close to H-score 0 is crucial to evaluate a potential PTEN-.
Mindful of the discrepant results for the 138G6 antibody, we first evaluated different staining protocols for PTEN IHC across the European Thoracic Oncology Platform (ETOP) laboratories and determined an optimal H-score threshold value for PTEN-. The SP218 clone was used alongside the established 138G6 and 6H2.1 antibodies. Pathologists' H-scores were compared with a novel approach of objective computerized pixel-based intensity measurement calibrated by pathologists. We investigated the prevalence of PTEN-and its correlation with clinicopathologic data in the ETOP Lungscape cohort of 2245 resected NSCLC patients. Table 1) .
Material and Methods

External Quality Assessment of PTEN IHC
Overall, 12 cases were retrieved from our archive according to the PTEN IHC result indicated in the signout report using the 6H2.1 antibody. These 12 cases included five positive and five negative surgical specimens, respectively, and two cell lines, PTEN-PC3 and PTENþ H460. 24 Firstly, whole sections were centrally stained and digitized on a webbook (Institute of Pathology Zurich) using all three antibodies. Secondly, these cases were assembled in tissue microarrays (TMAs) and stained locally (each ETOP laboratory). Locally stained TMA sections were sent back to Zurich for computer analysis. To compare SP218 data with the 136G6 antibody, we performed IHC on the Zurich ETOP TMAs (n ¼ 305 patients) with the latter antibody.
First, a visual presentation was given to train pathologists, including low-expression cases of H-scores of 50 or less. IHC results were discussed at a follow-up meeting. Second, PTEN staining and H-scoring instructions were distributed. Pathologists received all EQA results from their colleagues and associated statistics. Scoring results were examined by U.R. and A.S. and discussed with pathologists. Third, permission for further staining and scoring of the entire ETOP cohort with the SP218 antibody was delivered.
ETOP NSCLC Patient Lungscape Cohort and Website Databases
The iBiobank has annotated comprehensive data from 16 ETOP sites on surgically resected 2245 patients with stage I to III NSCLC with at least 3 years of followup (median follow-up, 4.8 years) full clinical history. 25, 26 The iBiobank also contains data on EGFR, BRAF, KRAS, PIK3CA alterations, and ALK receptor tyrosine kinase and MET receptor tyrosine kinase IHC. Research was conducted according to each participating country's ethics and regulatory requirements for use of patient material in research. We additionally performed in silico PTEN mRNA expression analysis from the Kaplan-Meier Plotter database (www.kmplot.com), consisting of 1145 lung cancer cases, including 673 LADCs and 271 LSCCs. 27 
PTEN Fluorescent In Situ Hybridization
EQA TMA sections of 4-mm thickness were incubated with a dual color probe for cytoband 10q23 and region 10p11.1-q11.1 (LSI PTEN Spectrum-Orange and CEP10 Spectrum-Green, Vysis/Abbott Molecular, Baar, Switzerland). For each case, 100 nonoverlapping nuclei were evaluated on a Zeiss Axioskop (Oberkochen, Germany). Z-stacks of 20 images with 0.5-mm step distance were merged.
H-scoring of PTEN IHC by Pathologists and Computer
ETOP Lungscape pathologists determined H-scores on webbook and TMA sections. The semiquantitative score was obtained by the summation of the product of total cellular PTEN immunoreactivity intensity (0, 1, 2, or 3) with corresponding percentage of stained tumor epithelia (H-score range, 0-300). Robust PTEN expression (score 2 or 3) in cancer-associated fibroblasts (CAFs), endothelial cells, and alveolar pneumocytes served as internal control.
Stained sections were digitalized using a NanoZoomer Digital Pathology scanner (Hamamatsu, Japan) at the maximum in-built magnification of 400Â. Image analysis was performed at 200Â magnification on the virtual microscope software Leica SlidePath. Tagged image file format pictures of tumor epithelia only were analyzed using Image-J2 software. 28 Pixel-based measurement of immunoreactivity was performed using the Lab* color space (lightness [L] and two color channels [a, b] ). White areas lacking tissue were removed in the brightness channel, whereas blue counterstaining areas were removed from chrominance-a and -b. The resulting brown signal was thereafter located between red and yellow. The threshold between the background brown signal and specific immunoreactivity intensity score 1 was averaged from 110 representative image frames laid on faintly stained glass (10 frames), unstained tissue areas of a microfluidic tissue processor-based IHC (50 frames), and stainings without primary antibody (50 frames). 29 This background setting was maintained for all further analyses. Subsequently, three Zurich pathologists and 10 ETOP pathologists set their individual thresholds of brown intensity scores 3, 2, and 1 for the SP218 antibody (Supplementary Video). The 138G6 antibody stainings were scored by two other Zurich investigators.
Computer H-scores were calculated in the same way by multiplying percentage of positive pixel area with respective intensity. For the one EQA whole section and the four EQA TMA cores of each of the 12 cases, 50 frames in total were put on tumor epithelia in a semiautomated manner. For the 97 TMAs of the 2245 patient ETOP cohort (n ¼ 8980 cores), 4 frames per case were used, covering largest possible areas of only vital tumor but not CAFs or necrosis. For the computerized analysis of the full cohort, the Zurich settings were applied on all images from externally stained TMAs to provide uniformity. The frame sizes were in the range of 100-500 Â 100-500 pixels (1 mm ¼ 2.17 pixels), generally being larger in the ETOP cohort than in the EQA whole sections or the EQA TMA cores ( Supplementary Fig. 1 ).
Statistical Analysis
In the EQA dataset, the Wilcoxon nonparametric test checked for significant differences between PTENþ versus PTEN-cases. Sensitivity and specificity of H-score thresholds were calculated through receiver operating characteristic (ROC) curves. In the ETOP cohort, the prevalence of PTEN-and confidence interval (95% CI) was compared between patients with different clinicopathologic characteristics using the Fisher's exact and the Mantel-Haenszel tests. Associations between PTENand predictive markers were evaluated by two-way tables and the Cochran-Mantel-Haenszel test, stratified by histology.
Clinical outcome included overall survival (OS, time from surgery to death from any cause), relapse-free survival (RFS, time from surgery to first relapse or death from any cause), and time-to-relapse (TTR, time from surgery to first relapse). 25, 26 The effect of PTEN-on outcome was explored through Cox regression models, adjusted for a series of patient, tumor, and surgical characteristics and for mutations. Final models with significant outcome prognostic factors were based on the backwards elimination method (Wald's p ! 0.10). Hazard ratios (HRs) and Kaplan-Meier curves were used to illustrate observed differences in hazard.
In all exploratory analyses, results with two-sided p 0.05 were considered significant. Analyses were performed using SAS version 9.4 (SAS Institute, Cary, North Carolina) and R version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria).
Results
PTEN IHC
Routine diagnostic protocol was used for 6H2.1 antibody, but for the SP218 and 138G6 anti-PTEN clones, we implemented novel protocols. To avoid differences in preanalytical conditions, all labs used the Ventana Ultra automated platform with standardized reagents and the same batch of SP218 antibody (Supplementary Table 1) . Figures 1A and 1B show the performance of the three antibodies in a PTEN-mucinous endometrial carcinoma and representative images for different H-scores. The methodology of computerized intensity measurement calibrated by pathologists is presented in Figure 2 . Examples of EQA TMA staining quality among centers are presented in Supplementary Figure 2 for two cases. Table 1 summarizes IHC and fluorescence in situ hybridization (FISH) data from the 12-case TMA and whole sections webbook used for EQA. The webbook analysis yielded similar results for SP218 and 138G6 antibodies. 6H2.1 stained stronger than SP218 and 138G6 (Supplementary Table 2 ), as in Figure 1A for a single case (computer H-score 3 versus 0) and Figure 3A . All antibodies could separate PTEN-from PTENþ cases based on H-score average. All negative cases also showed a genomic PTEN loss, ranging from 0.90 down to 0.02 CEP10/PTEN ratios. Correlation of H-scores among the antibodies was highly significant (p values 0.002-0.003) with coefficients 0.78 (138G6/6H2.1), 0.78 (SP218/ 138G6) and 0.80 (SP218/6H2.1) (data not shown).
EQA
The trade-off between sensitivity and specificity for the EQA TMA data was more balanced for intermediate than high H-scores (ROC curves in Fig. 3B ). Analyses of these ROC curves showed that the optimal cutoff threshold of PTEN-is mean H-score less than 5 for computer and less than 8 for pathologists (values shown in Fig. 3B ). To address intratumoral heterogeneity, we calculated the variation coefficient among the H-scores of the 50 randomly selected frames of the PTENþ webbook whole sections. A value of 0.38 was obtained for the SP218 antibody indicating little variation.
ETOP NSCLC Lungscape Cohort
Because the two antibodies SP218 and 138G6 had similar performance in the EQA TMA, investigation was performed to assess if they are also comparable in a bigger sample size. Therefore, the Zurich part of Lungscape (n ¼ 305) was investigated by both SP218 and 138G6. Results of both pathologists' and computer scorings showed a strong correlation between these antibodies (Spearman correlation coefficient between the two antibodies: 0.73 for computer scores and 0.93 for pathologist's scores; p < 0.001 in both cases). SP218 was chosen for further analysis of the full ETOP Lungscape cohort.
In this cohort with available PTEN information, the median patient age is 66. 4 Correlations of PTEN immunoreactivity with clinicopathologic parameters are summarized in Table 2 . PTEN-, using defined cutoffs for SP218, was detected in Overall (n ¼ 2245), the median OS was 67.9 months (95% CI: 62.0-74.3 months), the median RFS was 50.8 months (95% CI: 45.8-56.4 months), and the median Figure 2 . Methodology of computerized analysis of phosphatase and tensin homolog (PTEN) immunoreactivity based on pathologists' calibrated pixel intensity measurement. In FIJI Lab color space, color threshold was adjusted, performing threefold background normalization and followed by averaged intensity calibration by pathologists. The threshold between brown signal intensity 1 and blue-grey color of hematoxylin/bluing reagent counterstaining with eventual faint brownish tone (intensity score 0) was averaged from 110 representative image frames laid on faintly stained glass, unstained tissue areas of a microfluidic tissue processor-based immunohistochemistry, and stainings without primary antibody. Thresholds for intensity 2 or 3 levels were averaged from 3 Zurich pathologists and used for H-score calculation. Note: For subsequent analysis of both external quality assessment and European Thoracic Oncology Platform (ETOP) cohort frames of size 100-500 Â 100-500 pixels were laid on tumor epithelia only.
TTR was 103 months (95% CI: 84.0-not estimable). For LADC, PTEN-(based on the pathologists' scores cutoff ¼ 0) was a negative prognostic factor for all endpoints: OS (p ¼ 0.004), RFS (p ¼ 0.002), and TTR (p ¼ 0.003) (data not shown). This negative effect of PTEN-is further shown when dividing the H-score averages in four levels ( 5, >5 to 20, >20 to <100, and !100) ( Supplementary Figs. 3A and B; p < 0.05 for both pathologists and computer). In the adjusted Cox model depicted in the forest plot ( Supplementary Fig. 4A ), the HR for PTEN-versus PTENþ was 1.21 (95% CI: 1.01-1.46; p ¼ 0.04) for the LADC and the pathologist threshold 0, indicating higher death risk by 21%. Similar results were obtained for pathologists' threshold 8, computer threshold 5 ( Supplementary Figs. 4B and C) .
Finally, the Kaplan Meier-plotter database of 1145 independent NSCLC patients was interrogated for PTEN mRNA expression dichotomized at the median. PTEN expression in all NSCLC correlated with better OS (HR: 0.49, p < 0.001), matching our results ( Supplementary  Fig. 5 ). Regarding histologic subtype, high PTEN expression in LADC, but not LSCC, was also associated with better OS (HR: 0.41, p < 0.001).
Comparison of Pathologists Versus Computer Scoring
The intraclass correlation coefficient (ICC) was calculated to evaluate the resemblances of H-scores of common cases among different centers participating in the EQA. The ICC of the EQA TMA PTEN stainings for pathologists was 0.72, whereas that for the computer was 0.66. The ICC of the EQA webbook for pathologists is 0.88 using the SP218 antibody.
Moreover, the EQA TMA analysis showed a lower intercenter variability for computer-derived H-scores compared to the pathologists. The difference in calibration threshold settings between three internal Zurich pathologists and 10 ETOP pathologists was minimal (Fig. 4A) . Furthermore, the computer H-scores were on average 54% lower than the pathologists were (Fig. 4B) .
Regarding the ETOP cohort analysis, significant correlations were found for pathologists versus computer scores per individual core and per average of the four cores (all coefficients >0.55; p < 0.001) (data not shown). Further analyses used the four-core average. The frequency distributions of pathologists and computer scores are shown in Figure 4C using five H-score categories: (1) 0, (2) >0 to 5, (3) >5 to 20, (4) >20 to <100, and (5) !100. As in the EQA TMA analysis, the computerized methodology generally produced lower H-score values with the exception of H-scores close to 0. In the range close to 0, pathologists mostly scored exactly 0, whereas the computer mostly gave values of 5 or less. The opposite phenomenon was observed in the high-expression range, where the pathologists scored higher than the computer.
Discussion
In this study, different IHC protocols were investigated in the multicenter ETOP Lungscape cohort to measure PTEN protein immunoreactivity on tumor epithelia of formalin-fixed paraffin-embedded tissue blocks of resected chemotherapy-naïve NSCLC patients. In our novel approach, pathologists calibrated the computerized image analysis of PTEN IHC. Thereby, pathologists' interpretations were directly compared with independent computer-calculated H-scores on scanned slides obtained from pathologists' own intensity settings on an individual basis.
PTEN IHC and FISH
Comprehensive PTEN IHC testing originally used three monoclonal antibodies (28H6, 10P03, and 6H2.1) and one polyclonal on endometrial carcinoma. 6H2.1-derived immunoreactivity correlated best with PTEN gene alterations. 30 Recent studies in prostate, renal cell, breast, endometrial, and vulvar carcinomas confirmed this finding. [31] [32] [33] [34] Novel clones such as 138G6, SP218, and D4.3 were developed and tested on genetically defined PTEN þ/-cell lines.
35 SP218 and 138G6 are rabbit monoclonal antibody (RabMAb) with high affinities of 10 -12 equilibrium dissociation constant (K D) in contrast to mouse monoclonal antibody (MmAb) with 10 -9 K D . In this study the MmAb 6H2.1 although stained stronger than the two RabMAbs. Based on EQA results, performance of 6H2.1 should rather be considered overstaining, as, for example, lung carcinomas with genomic PTEN-showed H-scores up to 63. The synthetic CTD peptide for SP218 and 138G6 is most likely the same, explaining the similar H-score values in the EQA. Lung cancer may show complex genomic alterations with subclonal deletions. We used the CEP10/ PTEN ratio to measure the global genomic PTEN status. Most PTEN-cases were close to hemizygous or homozygous loss, except for the mucinous endometrium carcinoma with a value of 0.90. Cells are ultrasensitive to subtle changes of PTEN dosage. Hypermorphic mice with a 20% reduction in mRNA PTEN levels have already developed a spectrum of tumors. 36 
Computerized Analysis of Semiquantitative Intensity Marks
In our computerized pixel-based methodology, chromogenic intensity levels were calibrated by averaged settings of surgical pathologists with more than 10 years of IHC experience. Such thresholds may serve as "intensity reference marks" to be put in the continuous variable of brown tone intensity. Evidently, the absolute position of the intensity marks 1, 2, or 3 on the 255 to 0 Lab scale would be dependent on the general staining intensity of a given antibody. Here, these marks were laid on the brown tone scale in a rather close and comparable fashion by pathologists. It remains to be seen if the use of the entire brown tone intensity spectrum as continuous variable would add further value in comparison to the intensity mark approach. In our study, total cellular immunoreactivity was scored. A drawback of this approach is the lack of intracellular signal localization to either cytosol or nucleus.
Computerized analysis of automated quantitative analysis-based immunofluorescence allowed for measuring cytosolic PTEN-in NSCLC. 37 More recently, chromogenic PTEN IHC was measured in NSCLC in the red-green-blue spectrum using Aperio ImageScope software and 6H2.1 antibody. 34, 38 A similar approach was used for scoring PTEN expression in larynx carcinoma. 39 Furthermore, its intracellular localization, intensity, and frequency was assessed using 3D Histech Panoramic Viewer software and antibody clones 6H2.1, 138G6, and Ab6-28H6. 40 
Comparison of Pathologists Versus Computer
ETOP pathologists were challenged with their own computerized intensity settings. They were asked to semiquantitatively set intensity thresholds on a computer screen on representative images. Thereafter, they scored the EQA webbook on screen. These scores were compared with computerized analysis on the same images using their own intensity settings. More narrow data was obtained by the computer.
Scoring of brown tone intensity of IHC by the human eye is assumed to be subjective. Agreement on scores 0 and 3 is usually high. Scores 1 and 2 are more critical, but reasonable interobserver kappa values of 0.7 or higher can be achieved if visual dictionaries are provided. 33, 41 The integration of various frequencies with different intensities is particularly challenging because the perception of immunoreactivity on tumor epithelia by the human eye will be influenced by the staining intensity of surrounding CAFs, a phenomenon called Chubb illusion. Chubb illusion is an error in visual perception in which the apparent contrast of an object varies substantially to most viewers depending on its relative contrast to the field on which it is displayed. 42 Therefore, high density of strongly PTENþ CAFs tends to result in lower PTEN scores for the tumor epithelia when assessed by pathologists but not by the computer.
Regarding perception of stained area, overscoring may occur due to the fact that strongly stained areas are preferentially recognized in terms of percent surface. Here lies the strength of objective pixel-based intensity measurements leading to approximately 50% lower but more homogenous scores. Intercenter variability was also lower when the computer was used, which is useful for multicenter studies. Pathologists downscaled small H-scores of up to 5 resulting from few brown pixels (computer), to the "0" value whereas brown intensities greater than 20 (computer) were overrated and given values often greater than 100.
Setting Intensity Threshold for PTEN-
Because of the absence of a consensus, different thresholds were considered: for pathologists 0 (a priori) and 8 (calculated), and for computer 5 (calculated). From a cell biological point of view, it is conceivable that alternative cutoff values beside the a priori H-score 0 could be used for correlation with clinicopathologic parameters. It is important but also challenging to set an optimal threshold in the lower range of H-scores. Computerized analysis is thereby of great help to distinguish small differences in brown tones. Admittedly, using the different thresholds 0, 5, or 8, no major differences in correlation between PTEN-and clinicopathologic parameters were found.
Correlation With Clinicopathologic Parameters
It has been shown that tumor cells are ultrasensitive to subtle PTEN dosage alterations, and a hypermorphic allele with a remaining 80% of wild-type activity increased tumor formation in mice. 43 Complete PTEN loss triggered cellular senescence, which protected against tumor initiation or progression. 44 Therefore, partial PTEN loss is advantageous for initial tumorigenesis, whereas complete loss promotes rapid tumor growth after senescence mechanisms are impaired in advanced tumors. Our data fit with this concept as larger tumors showed a stronger PTEN loss. Our results also confirm the dismal prognostic value of PTEN-in earlystage adenocarcinomas. 45 We observed a protein loss in 44% (pathologists, threshold 0) and 59% (computer, threshold 5) of NSCLC, respectively. The frequencies were 51%/65% for LSCC and 37%/54% for LADC. Our results thus match with other NSCLC studies where PTEN-occurred in 21% or 59% of LSCC, but 4% or 34% in LADC, respectively. 20, 21 These studies used the 138G6 antibody and PTEN-was defined as absence of any immunoreactivity.
Clinical Significance
The main goal of medical expert systems is not to replace human experts, but rather to support them. In digital pathology, computerized image analysis using pixel-based measurement is of great help for many tasks -such as measurement of immunohistochemical brown staining across tumor surfaces. Thus, using the computer we add value to H-scores.
Here, we present a novel approach of pathologist's calibrated IHC analysis of the PTEN protein. Pathologists thereby compare their interpretations with computercalculated H-scores derived from their own intensity settings. Because of unbiased integration of pixel intensities in a given frame-of-interest, more homogenous H-scores are achieved. Such algorithms may improve reproducibility of biomarker detection regarding epitope validation in international clinical trials that stratify patients according to protein expression values.
Conclusion
In summary, calibration of immunoreactivity intensities by pathologists, following computerized H-score measurements, has the potential to improve reproducibility and homogeneity of biomarker detection regarding epitope validation in multicenter studies. Such computerized measurements are able to deliver adequate data in the low expression range and to confirm pathologists' scorings regarding correlations with clinicopathologic parameters, including survival.
